A SNIPpet of safety:a Goldilocks approach in CAR-T therapy
Despite the remarkable efficacy of chimeric antigen receptor(CAR)T-cells in B-cell malignancies,their full potential in solid tumors has not yet been achieved.In a recent publication in Cell,Labanieh et al.developed a druggable CAR T-cell construct that allows optimal fine-tuning of CAR T-cells to achieve maximal efficacy and reduce toxicity.
With the advent of CD19 targeting using chimeric antigen receptor(CAR)T-cells,the potential of immunotherapy,in particular adoptive cell therapy,became a reality.CD19-directed CAR T-cells have been transformative-eradicating disease in the most chemotherapy-refractory patients,with potential to induce long-term durable remissions.While inflammatory toxicities related to T-cell expansion can be life-threatening,the iterative recognition of and approach to treatment of cytokine release syndrome(CRS)and sequelae thereof,along with the development of pre-emptive interventions and supportive care measures,1 facilitated the safe implementation across patient populations.Additionally,the tolerance for on-target,off-tumor targeting enabled implementation of a therapeutic approach where broad antigen targeting was not of substantial concern.
safety、approach、goldilocks、snippet、therapy
32
TP393.08;S;TM912
2022-08-09（万方平台首次上网日期，不代表论文的发表时间）
共2页
603-604
